Blog
RSS FeedPosted by Michael Wonder on 21 Feb 2023
Lutetium Lu 177 vipivotide tetraxetan for the treatment of adults with PSMA positive hormone-relapsed metastatic prostate cancer after two or more therapies
21 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 17 Feb 2023
Teclistamab for the treatment of patients with relapsed or refractory multiple myeloma after three or more therapies
16 February 2023 - Another new cancer medicine becomes an assessment non-starter. ...
Posted by Michael Wonder on 09 Feb 2023
Lorlatinib for the first-line treatment of patients with ALK positive advanced non-small-cell lung cancer
9 February 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 08 Feb 2023
Regorafenib monohydrate for patients with previously treated metastatic colorectal cancer
8 February 2023 - Regorafenib monohydrate is recommended as an option for the treatment of adults with metastatic colorectal cancer who ...
Posted by Michael Wonder on 08 Feb 2023
Nivolumab in combination with fluoropyrimidine- and platinum-based chemotherapy for patients with untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma
8 February 2023 - Nivolumab, when used in combination with fluoropyrimidine-based and platinum-based combination chemotherapy, is recommended as an option ...
Posted by Michael Wonder on 26 Jan 2023
More than 400 people set to benefit after NICE approves ground-breaking CAR-T therapy to treat aggressive form of blood cancer
26 January 2023 - Hundreds of people with an aggressive form of lymphoma are set to benefit from the first ...
Posted by Michael Wonder on 19 Jan 2023
NICE recommends all oral triplet regimen for patients living with relapsed or refractory multiple myeloma
19 January 2023 - Since its launch in December 2017, ixazomib has been funded through the Cancer Drugs Fund and has ...
Posted by Michael Wonder on 11 Jan 2023
Nivolumab in combination with platinum and fluoropyrimidine-based chemotherapy for the first-line treatment of patients with advanced, HER2 negative gastric, gastro-oesophageal junction or oesophageal adenocarcinoma
11 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 04 Jan 2023
Mobocertinib succinate for patients with advanced EGFR exon 20 insertion mutation positive non-small-cell lung cancer after platinum-based chemotherapy
4 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 20 Dec 2022
NICE recommends Enhertu for more people with advanced breast cancer
20 December 2022 - Hundreds more people eligible for breast cancer drug Enhertu as NICE recommends it for earlier stage ...
Posted by Michael Wonder on 15 Dec 2022
Pembrolizumab for the neo-adjuvant and adjuvant treatment of patients with early or locally advanced triple negative breast cancer
14 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 15 Dec 2022
Amivantamab for the treatment of patients with EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy
14 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 15 Dec 2022
Cabozantinib maleate for patients with previously treated advanced hepatocellular carcinoma
14 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 04 Dec 2022
Brexucabtagene autoleucel for the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukaemia
2 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 01 Dec 2022
Cemiplimab for the first-line treatment of patients wth advanced or metastatic PD-L1 positive non-small-cell lung cancer
1 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...